DODC
DODC is a psychedelic drug from the substituted amphetamine family which acts as an agonist of the 5-HT2A receptor. It is the 3,4-dichloro derivative of the well known psychedelic drug 2,5-dimethoxy-4-chloroamphetamine. DODC was first officially published in a patent filed by Gilgamesh Pharmaceuticals in 2020, though anecdotal reports suggest it had been synthesised by clandestine chemists and its activity established several years prior to this.